Physician profile
Wei Wong
NPI 1639551526
$2,070.92
in general payments reported to CMS, 2019-2025
16 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $69.36 · 2021: $263 · 2022: $294 · 2023: $301 · 2024: $254 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121 · Education: $30.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.60 |
| Education | $30.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $441.30 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $408.09 | 2019-2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $360.05 | 2021-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $196.71 | 2022-2025 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Travere Therapeutics, INC. | $122.77 | 2023-2025 | |
| Akebia Therapeutics INC | $112.93 | 2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $79.29 | 2021-2022 | |
| Horizon Therapeutics Plc | $41.27 | 2022-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $38.97 | 2021 | |
| Calliditas Therapeutics US INC. | $35.05 | 2023-2024 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $23.53 | 2023 | Lupkynis |
| Kyowa Kirin, INC. | $23.35 | 2023 | Crysvita |
| Alexion Pharmaceuticals, INC. | $23.27 | 2024 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $22.01 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $17.33 | 2023 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.